Today's news is great but IMO it would be quite premature for OMER to announce specific partner info before they get the formal approval in July.
Unanimous Recommendation to Grant European Marketing Authorization for Omidria Based on Benefit/Risk Profile -
SEATTLE, May 22, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Omidria® (phenylephrine and ketorolac injection) 1%/0.3%. Omidria is used during cataract surgery and other intraocular lens (IOL) replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and reduce postoperative eye pain. Cataract surgery and IOL replacement are among the most common surgical procedures worldwide, with approximately 3.9 million of them expected to be performed in Western Europe alone in 2015.
"For the quarter ended March 31, 2015, product revenue from the controlled launch of Omidria was $238,000"
About 500 doses of Omidria. Those might not all be uses. Some could be inventory at surgical centers.
4:30 PM EDT. Conference call and webcast.
Provectus Biopharmaceuticals' Abstract on Liver Cancer Accepted for Poster Presentation at European Society for Medical Oncology's 17th World Congress on Gastrointestinal Cancer
Phase 1 Study Data to be Presented in Barcelona During WGI 2015, July 1-4, 2015
Thursday April 30, 2015
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc, a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"), announced today that the European Society for Medical Oncology (ESMO) has accepted the Company's abstract, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver," for poster presentation at the ESMO 17th World Congress on Gastrointestinal Cancer.
The conference runs July 1-4, 2015, and is being held at The International Convention Center of Barcelona, in Barcelona, Spain. The Company will post the presentation on its website at the time of the presentation.
The abstract, number P-116, will be available online on June 24, 2015. Provectus will provide more details about the presentation and conference as they become available.
The link is easy to get to ....... trustintelligence (+ (phonetic) daht kahm)
Click on "Trust Intelligence Discussion Forums"
Click on "BIOTECH: PROVECTUS (PVCT) + OMEROS (OMER) + more" toward bottom, under "Forum"
Click on "Omeros Corporation (OMER)"
Post #5 has the pros/cons
Alan Ross discusses this topic and provides links to articles in post #5 on the Omeros thread at TrustIntelligence daht kahm. It'll be interesting to see if that phonetic version of a link works. :-)
Prescient Investment Analysis
Disclosure: The author is long OMER.
Value, growth at reasonable price, event-driven
Omeros Corporation's Omidria Has Hallmarks Of Success
Apr. 16, 2015 2:31 PM ET
•There are multiple reasons that Omidria can be successful.
•Safety, ease of access, reduced stress on surgeons, and reimbursement are among them.
•The product's value appears substantial to investors.
Provectus Biopharmaceuticals Opens Patient Enrollment; Begins Phase 3 International FDA Comparative Clinical Trial of PV-10 for Melanoma
Interim Data Expected When 50% of Events Achieved
Wednesday April 15, 2015
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus"), enters phase 3 and has opened enrollment of patients for its phase 3 international FDA comparative clinical trial of PV-10 for melanoma. The Company is seeking 225 patients and enrollment has begun at St. Luke's University Hospital and Health Network, Bethlehem, PA, the first study site to be opened, with additional sites to be added in the coming weeks and months.
"Compassionate Use Approval Provides Glimpse of Trial Efficacy"
The article is available at the Trust Intelligence Forum.
Lengthy Omidria history. Not sure why so much was included.
OMS721 compassionate use approval in Europe was included, so very up-to-date.
Quite a few GPCR charts .... more than normal. Maybe something brewing? (Label that wishful thinking until something actually happens.)
They're quite different from the usual and are available on their website.
Try calendar area .... events .....
Downloadable "Omeros Corporation Corporate Presentation" low on the page
European Regulatory Authority Approves Clinical Investigator's Request for Compassionate Use with Omeros Corporation's OMS721
Date(s): 14-Apr-2015 7:01 AM
-- Patients with Thrombotic Microangiopathy Will Now Be Able to Receive Extended Treatment -
SEATTLE, April 14, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the presiding European regulatory authority has approved the company's investigational product OMS721 for compassionate use. OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of thrombotic microangiopathies (TMAs), including atypical hemolytic uremic syndrome (aHUS). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain.
The two patients in the compassionate-use study suffer from aHUS and were enrolled in the first cohort of the Phase 2 clinical trial. Based on improvements across markers of disease activity in that cohort, the investigator requested that Omeros continue to provide OMS721 so that the patients could extend their treatments. Following regulatory approval, Omeros was pleased to release shipment of OMS721 to continue treatment of these patients.
Omeros' ongoing OMS721 Phase 2 study continues to progress through its dose-ranging phase. The second cohort of patients, which received a higher dose than the first cohort, has now completed treatment. Following a pre-planned data review by internal and external physicians, if the safety data from the second cohort are acceptable, a recommendation will be made to advance as scheduled to a third cohort at an even higher dose. This third cohort could begin dosing before the end of April.
[more in news release]
Right jbg ......
SEATTLE, April 9, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 14th Annual Needham Healthcare Conference in New York next week. The presentation is scheduled for Tuesday, April 14 at 10:40am EDT.
The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page under the Investors section of the Company's website.
New Alan Ross article on SeekingAlpha
"Wedbush analyst Liana Moussatos reiterated an Outperform rating and boosted her price target on Omeros Corp. (NASDAQ: OMER) to $61.00 (from $54.00) after the company announced the US commercial launch of OMIDRIA
Moussatos commented, "We have increased our multiple on peak OMIDRIA sales to 10x from 9x to reflect the reduced risk with commercial launch. We calculate our 12-month price target by projecting present day fair value by 12 months. Our present day fair value is based on a sum-of-parts with each part's value calculated using a 30% annual discount from our net peak annual sales estimate to present day for each product and indication with clinical proof-of-concept for efficacy, then applying a 1-10x multiple depending on stage of development to reflect risk.""
Check your news source for this headline ....
"Seattle biopharmaceutical company Omeros launches first commercial product"
Dr. Donnenfeld is a consultant/advisor to OMER according to Acuity Advisors, LLC, and he is the immediate-past president of the American Society of Cataract and Refractive Surgery, Editor in Chief of Cataract & Refractive Surgery Today and EyeWorld; and Past president of Ocular Microbiology and Immunology Group. Therefore, IMO, his words have a high level of credibility.
Zacks: Omeros Receives Average Rating of “Strong Buy” from Analysts (NASDAQ:OMER)
March 24th, 2015
Omeros (NASDAQ:OMER) has earned an average broker rating score of 1.20 (Strong Buy) from the five analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and four have given a strong buy rating to the company. Omeros’ rating score has improved by 20% from 90 days ago as a result of various analysts’ upgrades and downgrades.
Analysts have set a 1-year consensus price target of $38.50 for the company and are forecasting that the company will post ($0.66) EPS for the current quarter, according to Zacks. Zacks has also given Omeros an industry rank of 112 out of 265 based on the ratings given to related companies.